1189709-96-3
1189709-96-3
Chemical Structure
5-Aminosalicylic acid-13C6
Synonym(s): Mesalamine-13C6;5-ASA-13C6;Mesalazine-13C6
- CAS No.: 1189709-96-3
- Formula:C13C6H7NO3
- Molecular Weight:159.09
IUPAC Name: 5-amino-2-hydroxybenzoic-1,2,3,4,5,6-13C6 acid
InChIKey: KBOPZPXVLCULAV-IDEBNGHGSA-N
SMILES: OC([13C]1=[13C]([13CH]=[13CH][13C](N)=[13CH]1)O)=O
Biological Activity: 5-Aminosalicylic acid-13C6 is the 13C labeled 5-Aminosalicylic Acid[1]. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
5-Aminosalicylic acid-13C6 | 5-Aminosalicylic acid-13C6 is the 13C labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Aminosalicylic Acid (Standard) | 99.54% | 5-Aminosalicylic Acid (Standard) is the analytical standard of 5-Aminosalicylic Acid. This product is intended for research and analytical applications. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Aminosalicylic acid-d3 | 99.38% | 5-Aminosalicylic acid-d3 is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Aminosalicylic acid-d3 disodium | 5-Aminosalicylic acid-d3 disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Aminosalicylic acid-d7 | 5-Aminosalicylic acid-d7 (5-ASA-d7; Mesalamie-d7; Mesalazie-d7) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Aminosalicylic Acid-d3 hydrochloride | 99.00% | 5-Aminosalicylic Acid-d3 (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Aminosalicylic Acid | 99.97% | 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Dammann K, et al. PAK1 modulates a PPARγ/NF-κB cascade in intestinal inflammation. Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2349-60. [Content Brief]
- [3]. Fang HM, et al. 5-aminosalicylic acid in combination with Nimesulide inhibits proliferation of colon carcinoma cells in vitro. World J Gastroenterol. 2007 May 2813(20):2872-7. [Content Brief]
- [4]. Rousseaux C, et al. The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ. Carcinogenesis. 2013 Nov34(11):2580-6. [Content Brief]
